<h2 data-section-id="mn68q6" data-start="0" data-end="41"><strong>Gastroesophageal Reflux Disease Market</strong></h2>
<p data-start="43" data-end="453">The US <a href="https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market"><strong>Gastroesophageal Reflux Disease (GERD) market</strong></a> was valued at nearly USD 3.4 billion in 2025 and is expected to grow at a CAGR of 6% during 2026&ndash;2036. Rising disease prevalence, increasing awareness, and strong demand for effective acid-suppressive therapies are driving market expansion. The introduction of advanced potassium-competitive acid blockers (P-CABs) is also reshaping the treatment landscape.</p>
<h3 data-start="455" data-end="478"><strong data-start="455" data-end="478">Key Market Insights</strong></h3>
<ul data-start="479" data-end="662">
<li data-section-id="1dyktfj" data-start="479" data-end="522">US market size in 2025: USD 3.4 billion</li>
<li data-section-id="1x9osyj" data-start="523" data-end="556">Expected CAGR (2026&ndash;2036): 6%</li>
<li data-section-id="12jwrdx" data-start="557" data-end="604">Growing adoption of novel oral formulations</li>
<li data-section-id="dqil8f" data-start="605" data-end="662">Increased focus on durable acid suppression therapies</li>
</ul>
<p data-start="664" data-end="979">VOQUEZNA by <span class="whitespace-normal">Phathom Pharmaceuticals</span> and <span class="whitespace-normal">Takeda</span> has emerged as the first approved P-CAB in the US, offering faster onset and improved acid control compared to conventional PPIs. However, long-term PPI safety concerns and competitive therapies may challenge market growth.</p>
<h2 data-section-id="1qbswht" data-start="981" data-end="1028"><strong>Gastroesophageal Reflux Disease Epidemiology</strong></h2>
<p data-start="1030" data-end="1348"><a href="https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-epidemiology-forecast"><strong>GERD</strong></a> remains one of the most prevalent gastrointestinal disorders in the United States. In 2025, the total prevalent GERD population in the US reached approximately 65 million cases. Epidemiological trends indicate increasing diagnosis rates due to greater disease awareness and improved access to healthcare services.</p>
<h3 data-start="1350" data-end="1377"><strong data-start="1350" data-end="1377">Epidemiology Highlights</strong></h3>
<ul data-start="1378" data-end="1673">
<li data-section-id="w9to0n" data-start="1378" data-end="1430">Total prevalent GERD cases in the US: 65 million</li>
<li data-section-id="pj44e2" data-start="1431" data-end="1505">25%&ndash;40% of Americans experience symptomatic GERD during their lifetime</li>
<li data-section-id="dajclr" data-start="1506" data-end="1554">Around 7%&ndash;10% experience daily GERD symptoms</li>
<li data-section-id="101e481" data-start="1555" data-end="1601">Females account for nearly 60% of US cases</li>
<li data-section-id="176fftg" data-start="1602" data-end="1673">Non-Erosive Reflux Disease (NERD) represents about 70% of all cases</li>
</ul>
<p data-start="1675" data-end="1935">Women are more frequently associated with NERD, while men commonly present with erosive esophagitis. Epidemiology segmentation includes diagnosed prevalent cases, gender-specific cases, age-specific cases, grade-specific cases, and treated patient populations.</p>
<h2 data-section-id="1gzcmnc" data-start="1937" data-end="1980"><strong>Gastroesophageal Reflux Disease Pipeline</strong></h2>
<p data-start="1982" data-end="2289">The <a href="https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-pipeline-insight"><strong>GERD pipeline</strong></a> is evolving with the development of next-generation acid suppression therapies aimed at addressing limitations associated with traditional proton pump inhibitors (PPIs). Emerging therapies are primarily focused on improving symptom control, faster healing, and enhanced patient compliance.</p>
<h3 data-start="2291" data-end="2309"><strong data-start="2291" data-end="2309">Emerging Drugs</strong></h3>
<ul data-start="2310" data-end="2564">
<li data-section-id="1tzrn8j" data-start="2310" data-end="2437"><strong data-start="2312" data-end="2336">BLI5100 (Tegoprazan)</strong> &ndash; <span class="whitespace-normal">Braintree Laboratories</span>
<ul data-start="2381" data-end="2437">
<li data-section-id="14bbuc" data-start="2381" data-end="2401">Mechanism: P-CAB</li>
<li data-section-id="9balek" data-start="2404" data-end="2437">Route of Administration: Oral</li>
</ul>
</li>
<li data-section-id="1xnxle6" data-start="2439" data-end="2564"><strong data-start="2441" data-end="2463">Linaprazan glurate</strong> &ndash; <span class="whitespace-normal">Cinclus Pharma</span>
<ul data-start="2508" data-end="2564">
<li data-section-id="14bbuc" data-start="2508" data-end="2528">Mechanism: P-CAB</li>
<li data-section-id="9balek" data-start="2531" data-end="2564">Route of Administration: Oral</li>
</ul>
</li>
</ul>
<p data-start="2566" data-end="2842" data-is-last-node="" data-is-only-node="">The growing focus on advanced oral therapies is expected to improve treatment adherence and outcomes. Pipeline development is also targeting unmet needs such as persistent heartburn despite PPI use, Barrett&rsquo;s esophagus surveillance, and reduction of nocturnal reflux symptoms.</p>

Gastroesophageal Reflux Disease (GERD) Market

Gastroesophageal Reflux Disease Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape